The retinal ban made the headlines. But retinyl linoleate carries a 0.1% defined scope of assessment — and PIRs above that limit stopped being valid from 26 June 2026.

The decision everyone noticed, and the one they didn't

When AICIS published its evaluation of retinal (retinaldehyde) on 26 June 2026, the reaction was immediate and loud. The Exempted and Reported introduction pathways were prohibited for cosmetic end uses, effective the next day, and importing retinal became unlawful more or less overnight.

Published the same day, and attracting far less attention, was EVA00187 — Retinol and retinol esters.

That one hasn't produced headlines. But buried inside it is a detail with real consequences for anyone using retinyl linoleate — and AICIS has begun issuing compliance notices to affected introducers, advising that their introduction is not authorised.

Five chemicals, one defined scope

EVA00187 covers five chemicals: retinol (CAS 68-26-8), retinyl palmitate (79-81-2), retinyl acetate (127-47-9), retinyl linoleate (631-89-0) and retinyl propionate (7069-42-3).

The evaluation concluded that this group is expected to cause adverse effects on the development of the unborn child, with sufficient evidence to warrant classification as human developmental toxicants.

But only one of the five carries a defined scope of assessment as a term of its Inventory listing — retinyl linoleate. Its listing states that the chemical has been assessed as a component of dermal cosmetic products at concentrations no more than 0.1%.

That single line is what caught people out.

Why a defined scope bites

The practical effect of a defined scope is easy to underestimate. Introduce the chemical within the scope — at or below 0.1%, in a dermal cosmetic product— and your introduction stands. Introduce it outside that scope, and the chemical falls outside its Inventory listing altogether, which means it is effectively treated as a new chemical for categorisation purposes.

That matters because a Pre-Introduction Report (PIR) for a Reported introduction rests on the chemical's risk profile supporting the Reported category. Once the classification changes, that foundation goes. From 26 June 2026, PIRs covering retinyl linoleate above 0.1% ceased to be valid — not because the introducer had done anything wrong, but because the ground moved underneath them.

The parallel with retinal is close. In both cases, a position that was sound on 25 June was not on 26 June.

The good news, and it's genuine

If you introduce retinyl linoleate at 0.1% or below in a dermal cosmetic product, you are fine. You remain within the defined scope, your PIR stands, and there is nothing to do.

For a great many formulations, that is the end of the story. This is not a category-wide problem in the way the retinal decision was — it is a threshold problem, and the threshold is one most products sit comfortably beneath.

It's also worth being clear about what this isn't: the 0.1% limit attaches to retinyl linoleate alone. The other four chemicals in the evaluation do not carry it, and it should not be read as a blanket rule across retinol esters.

And AICIS has flagged that the 0.1% may not be permanent

Here's the twist worth knowing. AICIS has itself noted that the risks identified in this evaluation, and the means proposed for managing them, apply to all the retinol esters in the group — which means the retinyl linoleate term of listing is no longer aligned with its own latest risk assessment.

The evaluation accordingly recommends a future variation under section 86 of the Industrial Chemicals Act 2019 to update that defined scope of assessment.

So the 0.1% limit is live and binding today, but AICIS has signalled it intends to revisit it. Anyone affected should factor that into their planning — and keep watching, because the terms may shift again.

How you find out — and why that's the wrong way round

AICIS has been issuing compliance notices advising introducers that an introduction is not authorised, because it would not meet the criteria to be a Reported introduction.

By the time that notice arrives, you are already introducing without valid authorisation. That is an uncomfortable position, and an avoidable one — the information needed to work it out was published on 26 June, inside an evaluation statement most introducers had no particular reason to read closely, because it wasn't the one making news.

That is the real lesson. The evaluation that affects you is not always the one being discussed — and the detail that catches you is usually a level below the headline, in the terms of listing rather than the conclusion.

What introducers should do

  • Check whether retinyl linoleate appears in any of your formulations, at what concentration, and in what product type.
  • If you're outside the scope, stop and take advice before further introduction; the available routes are narrower and an assessed introduction may be required.
  • Read evaluation statements for the terms, not just the outcome. Defined scopes, concentration cut-offs and use conditions sit in the detail.
  • Watch for the section 86 variation, which may change the position again.
  • Review your other PIRs against recently published evaluations — this statement was one of eleven published on 26 June — and keep an eye on the Rolling Action Plan, where nine further evaluations recently commenced.

Where we fit in

This is exactly the sort of change that doesn't announce itself. It arrives inside a routine evaluation statement, takes effect immediately, and only becomes visible when a compliance notice turns up.

We monitor AICIS evaluations, Inventory listings and their terms, the Rolling Action Plan and Poisons Standard decisions on behalf of our clients — precisely so that a defined-scope change is something we tell you about, rather than something the regulator does. For clients whose formulations we already hold, checking a new evaluation against their range is short work, and considerably cheaper than responding to a notice after the fact.

Our staff have extensive regulatory experience including one who spent seven years at Australia's industrial chemicals regulator (NICNAS, now AICIS), so we understand how evaluations and assessment applications are handled from the inside as well as the outside.

Between us our directors bring around a century of combined regulatory experience in this area, including time inside the industrial chemicals regulator itself — so we read these decisions with a fair sense of how they will be applied in practice, not just what they say.

If you use retinyl linoleate, or you'd like your introductions checked against the June evaluations, we're happy to take a look.

This article is general information only and does not constitute regulatory advice for any specific product or introduction. Requirements and regulator positions change; confirm the current position before acting.

Further reading

Primary sources from AICIS:

‍

Written by 
Dr Renée Badenhop
Renee received a Bachelor of Science at the University of Sydney and a Bachelor of Science (Honours) at Macquarie University and in 1997 she was awarded a PhD (Medicine) at the University of NSW. In 2005 she completed a Master’s Degree in Industrial Property at the University of Technology. Renee has been Director at Engel Hellyer & Partners since 2013.